Clinical Trials
Advancing novel candidates with the highest likelihood of driving significant benefit for patients.
We’re committed to evolving immunology. Our pipeline includes programs that are targeted to address highly prevalent inflammatory diseases. Our goal is to drive meaningful advances for patients with these diseases, designing all our programs to deliver best-in-class profiles.
EVO756 is an orally administered, highly selective MRGPRX2 inhibitor being developed for patients with chronic spontaneous urticaria who remain symptomatic despite H1 antihistamine treatment. Evommune has initiated a Phase 1 clinical trial that is evaluating the safety/tolerability and preliminary activity of its MRGPRX2 antagonist inhibitor in healthy volunteers and patients with chronic spontaneous urticaria.
EVO756-CIU001 is a multi-center, Phase 2a study evaluating the safety, tolerability, and efficacy of EVO756 in adults with chronic inducible urticaria (either cold urticaria or symptomatic dermographism). All participants will receive open-label treatment with EVO756, once daily, for a 4-week treatment period. Participants will be evaluated for safety and efficacy at weekly visits during treatment and return to the clinic for final assessments 2 weeks following the last dose of study drug.
EVO756-HV001 is a Phase 1 randomized, double-blind, placebo-controlled study to evaluate EVO756 in healthy adults. The study is conducted in 2 parts. Part A will evaluate the safety and pharmacokinetics of single oral ascending doses of EVO756 in 7 cohorts of study participants and Part B will evaluate the safety, pharmacokinetics, and pharmacodynamics (effects on mast cells and skin reactivity) of EVO756 after 14 days of oral dosing in 5 cohorts of study participants.